PROCESS FOR THE PRODUCTION OF VIRUS IN CELL CULTURES

Abstract: The object of the invention is a process for the production of virus in cell culture with high yield and low levels of contamination by cell proteins, the virus being appropriate to be used in the preparation of seed lots and vaccines. As used herein, the term "virus" means inactivated virus, attenuated virus and recombinant virus, including chimeric virus. The process comprises the steps of: (a) preparing a culture of cells which are permissive to the virus and acceptable as a substrate for vaccine production; (b) suspending the cells in a suitable medium followed by cell seeding at low densities; (c) incubating the cell culture at 30 to 40 DEG C for an appropriate period of time; (d) removing the medium from the cell culture of step (c) and inoculating with seed virus; (e) incubating the cell culture of step (d) at 25 to 40 DEG C for an appropriate period of time; (f) removing the medium followed by washing the cells once or more times and replacing the medium; (g) incubating the cell culture of step (f) at 25 to 40 DEG C for an appropriate period of time; (h) total or partial harvesting of culture supernatant containing virus with or without addition of stabilizer; (i) optionally, carrying out multiple harvests of virus containing medium, at any desired interval, by replacing the removed medium and re-incubating the culture for an appropriate period; (j) optionally, removing the cell debris and whole cells from the harvested virus; (l) optionally, virus inactivation and; (m) storing the virus at -45 DEG C or lower.

Description: 1 Title Process for the production of virus in cell cultures The present invention relates to the production of vaccine v iruses in cell cultures at high virus vields particularlv for the production of Flaviviruses in fibroblast cell cultures and more particularlv for production of anv substrain of the 17D veilovv fev er virus in culture of chick embrvo fibroblasts The virus present in a vaccine preparation can be obtained by inactivation attenuation and genetic modification through recombinant DNA technology BACKOR. )I JND ( >r THE INVLNTK)N Conventional vaccines are usually prepared by producing large amounts of virus in cell tissue culture or in laboratory animals and then rendering the virus harmless without destroying its immunological properties Traditionally, this is accomplished either bv inactivating the infectivity of the virus or by selecting an avirulent or attenuated virus for use in live vaccines Attenuation is often established by adapting the virus to unusual growth conditions (1 e . different animal hosts or cell cultures) and bv frequent passages in cell culture of large viral inocula to select mutants which have lost virulence and thus produce minor or no clinical symptoms On serial passage in cell cultures, attenuated vaccine viruses can potentially revert to the virulent phenotype by mutation or selection For a subpopulation in the original virus preparation, it is common practice therefore to use a seed lot system in which an original virus preparation, shown to be attenuated for man. is passaged once to give multiple ahquots of primary (master) seed One or more a quots of virus from this pπmarv seed is passaged once further to give a secondary (working) seed preparation One or more ahquots of this secondary seed preparation are used in the production of one batch of vaccine In this way, serial passage can be limited and the probability of selection or mutation minimised An example of this method to obtain attenuated vaccine viruses is the production of Yellow Fever (YF) vaccine strains In Figure 1A the passage history of the original YF Asibi strain and derivation of YF 17D vaccine strains and its substrains is depicted The YF virus Asibi strain was subcultured in embryonic mouse tissue and minced whole chicken embrvo with or without nervous tissue These passages yielded the parent 17D strain at passage level 180 17DD at passage 195 and 17D-204 at passage 204 17DD strain was further subcultured until passage 241 and underwent 43 additional passages in embryonated chicken eggs at passage 284 which corresponds to the vaccine batches produced nowadays in use for human vaccination The 17D-204 was farther subcultured to produce Colombia 88 strain which upon passage in embryonated chicken eggs, gave rise to different vaccine seed lots currently in use in France (I Pasteur, at passage 235), in the United States (Connaught. at passage 234) The 17D-213 strain was derived from 17D-204 when the pπmarv seed lot (S I 1 12-69) from the Federal Republic of Germany (FRG 83-66) was used bv the World Health Organization (WHO) to produce an avian leukosis virus-free 17D seed (S I 213/77) at passage 237 New 17D substrains have been developed through the use of recombinant DNA technology which required a better knowledge on flavivirus genome structure and expression The Yellow Fever vims is the prototype virus for the Flavivirus genus within the Flavrvindae family of positive-stranded RNA viπjses The flaviviruses are spherical v iruses with 40-60 nm in diameter w ith an icosahedral capsid which contains a single positive-stranded RNA molecule and viral replication takes place entirely in the cell cytoplasm The YF virus RNA genome consists of 10,862 nucleotides in length with short 5' ( 1 18 nucleotides) and 3 ' (5 1 1 nucleotides) untranslated regions, a 5 cap structure and nonpolvadenylated 3 ' end This single RNA is also the viral message and its translation in the infected cell results in the synthesis of a polyprotein precursor which undergoes posttranslational. proteolvtic processing to generate 10 virus-specific polypeptides In order to manipulate RNA genomes at any particular site, complementary DNA s corresponding to the complete genome must be available The pioneer study of Rocaniello and Baltimore (Rocamello V R and Baltimore, D ( 1981 ) "Cloned poliovirus complementarv DNA is infectious in mammalian cells" Science 214 916-919) first showed the feasibility to generate vims from cloned cDNA With the development of //? vitro transcription systems (see Melton D A , Kπeg, P A , Rabaghati M R . Maniatis, T , Zinn. K and Green. M R ( 1984) Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteπophage SP6 promoter ' Nucl Acids Res 12 7035-7056) it became possible to synthesize /// vitro fall-length viral RNA with a much higher efficiency as compared to cDNA transcription in the cell The development of more efficient transfection methodologies such as cationic liposomes and electroporation helped improve the efficiency of transfection of cultured cells with RNA The basic methodology for what is known today as infectious clone technology was set For a number of positive stranted vimses. infe ious cDNA has been obtained and can be used to understand the molecular basis of several biological phenomena including attenuation A fall-length cDNA was first developed for YF v -.rus and demonstrated to give rise to a vims after transfection of cultured vertebrate cells with /// vitro synthesized RNA in 1989 (Rice et al, 1989) The derivation of YF infectious clone progeny vimses is depicted in Figure IB The viral RN of 17D substrains boxed in Figure 1 named F-204, C-204, 17D-213 and vaccine 17DD have been the subject of complete nucleotide sequence determination bv different groups and published elsewhere Each of the 17D-204 substrains, F-204 and C-204 was plaque purified in different cell lines, and the obtained plaque-purified vims was amplified in SW13 cells and used for cDNA cloning and sequence analyses For 17D-213 and 17DD vimses. RNA was extracted directly from vims which had been purified from the vaccine preparation, and these populations are therefore more likely to represent the sequence which should confer an attenuated phenotype to the vaccine vims The only YF infectious cDNA derived to date was originated from the C-204 cDNA library (Rice, C M , Grakoui. A , Galler. R and Chambers, T ( 1989) "Transcription of infectious yellow fever RNA from full-length cDNA templates produced bv /// viti o hgation" The New Biologist 1 285-296) but the charatenzation of vims recovered from it after transfection in CEF cells (YFιv5 2/SL at passage 241 ) and one passage in embryonated eggs using current manufacturing methodology (YFιv5 2/VL at passage 242) revealed a vims with an unacceptable degree of neurovirulence for nonhuman primates and therefore not suitable to be tested for human vaccination (Marchevskv, R S , Mariano, J , Ferreira V S , Almeida E , Cerqueira M J , Carvalho R , Pissurno, J W Travassos da Rosa, A P A Simόes M C Santos. C N D , Ferreira, 1 1 Muylaert. I R Mann, G F , Rice C M and Galler R "Phenotypic analvsis of yellow fever vims derived from complementary ' DNA Am J Trop Med Hvg , 52( 1 ), pp 75-80, 1995) Comparison of the nucleotide sequences for the 17D- 13 and 17DD substrains depicted in Fig 1 A led to the genetic modification of the cDNA of C-204 vims rendering it more DD- ke This new cDNA was used to direct the /// 3 viv o nthesis of RNA which upon transfection of CEF cells gav e rise to a new seed vims named YFivό 2/DD at passage 241 This vims was then used to prepare the pπmarv and secondary seed lots, both in CEF, at passages 242 and 243. respectively as described in the Patent Λ.pphcatιon BR PI 9701774 filed in the name of the same applicant of the present invention In short, given the well known vaccine properties of YF 17D vims with regard to safetv and efficacy, the capability to manipulate its genome paved the wav to its dev elopment as a vector to direct the expression of antigens from other pathogens Regardless the vaccine vims is obtained bv inactivation, attenuation or the use of recombinant DNA techniques, the vims must be compatible with the host cell, I e capable of autonomous replication in the host cell Moreover in the large-scale production, the host cell must be a cell insofar as the vims can grow there with high vield Cells for the production of live vims vaccines for parenteral use in man are limited to those which are free of adventitious agents, non-tumoπgenic and karvologically normal Such cells include pnmarv or serially passaged cultures derived from a vaπetv of mammalian or avian tissues such as human diploid fibroblasts (e g , MRC-5), monkey kidney (MK), avian embrvo fibroblasts (e g . chick embryo fibroblasts) and many others These cells are infected with the v ims ("seed vims") which then replicates in the cell and is usuallv released into the culture medium The conditions and materials used in the whole process must be carefallv monitored to avoid problems mainly related to genetic variability, loss of immunogenicity, vims inactivation, neurovirulence. low yield in relation to vims input and contamination by extraneous agents In the US 5,391,491 and US 5,550,051. it is proposed a method of producing vims/vims antigen, in partichr the flavivirus tick-borne encephalitis vims, by infecting a biomass comprised of avian embryo cells aggregates having diameters of between 100 μm and 1 000 μm with the said vims in a culture medium having an oxygen concentration of at least 0 01 mmol/1, the cell aggregates being present in a concentration of at least 10 mg of cell aggregates per ml The applicant mentioned that the control of the aggregates size and the oxygen concentration aims both to reduce the contamination of cell proteins in the medium caused by the gradual cell lysis and to increase the reproducibility of the viαis/ virus antigen which is low when individual cells or small aggregates are present in suspension It is also described that measurements demonstrated that TBE-virus/virus antigen production will be stronglv reduced on a larger scale in a culture having a cell density of 2 \ 10 cells per milhliter that communicates with the oxygen atmosphere exclusively by its surface Several attempts have also been made to preserve the lmmunogemcit of the vaccine vims US 5,021,347 describes a recombinant vaccinia vims expressing the E- protein of Japanese encephalitis vims aiming to avoid the decay of the lmmunogenic properties of the vaccinal vims The animal culture cell used in the infection with the vims is anv cell insofar as vaccinia vims can grow there Specific examples of culture cell cited in the patent include TK- 143 (derived from human osteosarcoma). FL (derived from human amnion). Hela (derived from carcinoma of human uterine cervix), KB (derived from carcinoma of human rhinopharvnx), CV-1 (derived from monkey kidnev), BSC- 1 (derived from monkev kidney), RK13 (derived from rabbit kidnev), L929 (derived from mouse connective tissue), CE (chicken embryo) cell. CEF (chicken embrvo fibroblast) cells In addition in Marchevskv et al (Marchevsky et al, 1995), pπmarv culture of certified SPF (Specific Pathogen Free) chicken embrvo fibroblasts (CEF) for human vaccine production are mentioned as appropriate in the preparation of the master seed lot of a recombinant YF vaccine vims Despite the advantages of using certified SPF-CEF cells to produce vaccine vimses. such as YF measles, mumps, rubella., it is frequently found that the process is relatively uneconomic due to low yields This is particularly tme for the YF vaccine vims produced in CEF at the cell densities normally used ( 1 x 10 6 cells/cm 2 ) where yield is directlv related to vims input Thus the amount and cost of the seed vims necessarv under these conditions is too high due to the need for costly neurovirolence tests on each seed lot The conditions for optimal vims production must be carefully controlled in terms of incubation temperature and time, cell seeding density and vims inoculum In addition, a number of other factors determine vims yield Thus, some vimses readily generate defective interfering particles which are avoided by using low vims inputs Some vimses are good inducers of interferon and may be sensititive to its action The stability of vims in the culture medium which is being used is also of vital importance since yield is a balance between production and loss of infectivity The role of interferon in the vims/cells system has been studied since interferon was discovered bv Isaacs and Lindemann (Isaacs A and Lindemann, J Proc Rov Soc Ser B , 147 258 1957) Interferons are materials having antiviral properties and are produced bv certain tvpes of cells which have been stimulated bv exposure to a vims, certain nucleic acids, or antigen/mitogen complexes Mammalian and avian interferons fall into three main categories, alpha, beta and gamma .Alpha interferon is produced by leucocytes, beta bv fibroblasts and gamma by T lymphocytes and natural kil' r cells stimulated by alloantigens, tumors, and mitogens All three are secreted by the respective cells after the cells are stimulated bv a vims or other inducer The interferons are frequently referred to the cell of origin and. therefore, gamma interferon is also known as "immune" interferon Interferon activitv is traditionally determined based on its ability to induce resistance in cells which where challenged with an interferon sensitive vims In the production of vaccine vimses in cell cultures, the interferon system is responsible for low vims yields of some vaccine vimses since they may be good inducers of interferon and/or sensitive to its action The 17D yellow fever vaccine vims is both a good inducer of interferon and extremely sensitive to its action Indeed the interferon activity is the ability of cells to resist to a vims challenge Thus interferons are potentially potent dmgs which show promise as clinical antiviral agents If the antiviral activity of the interferons is an advantage in relation to the treatment of humans against diseases caused by vims, it is a disadvantage when dealing with the /// vitro production of vims because the interferons inhibit, specifically, the replication of vims in cells This is probably the main cause of the low yields in the production of manv vaccine vimses Consistently, the FR 2 689 519 patent application proposes a process of in vitro cultuπng cells infected with a vims associated with sclerosis in which a primary cell culture is infected with the vims in a culture medium containing polvclonal antibodies anti- interferon-beta to inhibit the antiviral activity of the interferon-beta The disadvantage of the process is the addition of contaminant antibodies which can be difficult to separate from the desired product, thus limiting its usefulness in vaccine vims production Accordingly there is a great need for an improved process to produce interferon inducing/sensitive vaccine vimses without the disadvantages mentioned above SUMMARY OI THΓ INVENTION The object of the invention is a process for the production of vims in cell culture with high yield and low levels of contamination bv cell proteins the vims being appropriate to be used in the preparation of seed lots and vaccines As used herein, the term 'virus means inactivated vims, attenuated vims and recombinant vims, including chimeπc vims Particularly the chimeπc vims may has a genome comprising nucleic acid sequences encoding, at least, one structural protein from one flavivirus and nucleic acid sequences encoding the remainder of the genome of another flavivirus to make it functional More particularlv the chimeπc vims mav have a genome comprising nucleic acid sequences encoding at least one stmctural protein from one flavivirus and nucleic acid sequences encoding the remainder of the genome of YF 17D vims to make it functional In one embodiment, the present invention relates to a process which comprises the steps of (a) preparing a culture of cells which are permissive to the vims and acceptable as a substrate for vaccine production, (b) suspending the cells in a suitable medium followed by cell seeding at low densities (c) incubating the cell culture at 30 to 40 °C for an appropriate period of time (d) removing the medium from the cell culture of step (c) and inoculating with seed vims, (e) incubating the cell culture of step (d) at 25 to 40° C for an appropriate period of time, (f) removing the medium followed by washing the cells once or more times and replacing the medium, (g) incubating the cell culture of step (f) at 25 to 40° C for an appropriate period of time, (h) total or partial harvesting of culture supernatant containing vims with or without addition of stabilizer, (l) optionally, carrying out multiple harvests of vims containing medium at any desired interval, by replacing the removed medium and re-incubating the culture for an appropriate peπod, (j) optionally, removing the cell debris and whole cells from the harvested vims, (1) optionallv, vims inactivation and. (m) storing the vims at -45° C or lower In another embodiment, the present invention relates to a process for the production of Flavivirus vaccine in cell cultures comprising the steps of (a) preparing a culture of cells which are permissive to the vims and acceptable as a substrate for vaccine production (b) suspending the cells in a suitable medium followed by cell seeding at low densities, (c) incubating the cell culture at 30 to 40 °C for an appropriate period of time, (d) removing the medium from the cell culture of step (c) and inoculating with seed vims, (e) incubating the cell culture of step (d) at 25 to 40° C for an appropriate period of time, (f) removing the medium followed bv washing the cells once or more times and replacing the medium, (g) incubating the cell culture of step (f) at 25 to 40° C for an appropπate peπod of time, (h) total or partial harvesting of culture supernatant containing vims with or without addition of stabilizer (1) optionallv, carrying out multiple harvests of vims containing medium at any desired interval bv replacing the removed medium and re-incubating the culture for an appropπate period 0) optionally, removing the cell debris and whole cells from the harvested vims, (1) optionally, vims inactivation and, (m) optionally, lvophi zing the vaccine composition of steps h I j or 1 to obtain a freeze dry form of the vaccine composition Whether stabilizer is used it av be added to the vims harvested at steps with medium changing prior to storage at -45° C to -196° C The vaccine product appropriately contains no significant levels of host cell proteins e g chicken proteins (< 100 nanograms/ human dose) The present inv ention represents a breakthrough frtflhe ^rc@jcjrfo^f| ε-Q IcisΛid vaccine vims and is characterized bv a fine control of the conditions and starting materials such as the densitv and type of cells to be infected with vims vims input and use of stabilizers BRIEr DESLRIP I K )N ( )F THE DRAW INGS FIGURE 1 illustrates the passage history of the original YF Asibi strain and derivation of YF 17D vaccine strain and its substrains (A), and the YF infectious clone progeny vimses (B) FIGURE 2 illustrates the YF 17D vims strain vield related to the incubation time (A), the level of induced interferon in relation to the incubation time (B) and the degree of resistance to Sindbis challenge with the incubation time (C) FIGURE 3 shows the interferon mediated inhibition of Sindbis vims in cultures of chick embrvo fibroblast cells infected with the YF 17D vims strain The cultures were infected with serial dilutions of YF vims and incubated at 37°C 5 hours later (A), 24 hours (B) and 72 hours (C) the cultures were submitted to Sindbis vims action FIGURE 4 shows the influence of the pretreatment of the cells with actinomvcin D referring to the induced interferon with the incubation time (A) and referring to the YF 17D vims strain yield with the incubation time FIGURE 5 diagrammaticallv ^hows the prototype stmcture of the Flavivirus genome and the stmcture of chimeπc vimses obtained by using the methology of the present invention DETAILED DESCRIPTION OF THE INVENTION Several factors can influence the vield of vims The high degree of puπtv required for potentially administrate vaccines limits the alternative methods which can be applied to vims yield improvement In the International Symposium on Yellow Fever and Dengue - Fifty years from the introduction of the 17D strain in Brazil, Rio de Janeiro Brazil Mav 15- 19 1988 it was discussed the necessitv of improving the process of production of YF vaccinal vims Lopes O S , (Lopes, O S, "Development of a Yellow Fever vaccine in tissue culture ' ]n International Symposium on Yellow Fever and Dengue - Fifty years from the introduction of the 17D strain in Brazil Annals) introduced the use of CEF cells culture in the production of YF 17D vaccine vims The incentive to use cells culture instead of chicken embrvo was to overcome several important problems related to the high egg protein content of the vaccine (up to 250 μg of chicken protein per human dose) and difficulties related to expanding-scale production While Lopes, O S has cited the use of CEF cells as a potential solution to the above mentioned problems a very important production feature remained to be solved namelv the low yield of vims produced relative to the amount of seed vims used This <s one reason why yellow fever vaccines are still produced by the viral inoculation of chi mbrvos m- ovo Studies on the replication of the YF I 7D v ims in CEF were carried out to know which factors cause the reduction in vims vield The factors investigated were the presence of defectiv e interfering (DI) particles the induction of interferon and sensitivitv to its action and the effect of cell seeding rates Tables I and II and figures 2 and 3 show the results of experiments using YF 17D- 13 vims in CEF This YF 17D substrain was used because it is the vims seed from WHO known to be free of avian leukosvs vims complex and its attenuated phenotvpe and immunogenicitv are well characterized in both nonhuman primates and humans In addition it was the substrain recommended bv WHO to be employed in order to establish production of YF 17D vaccine in cultured cells and accordingly it was the vims used bv O S Lopes for the initial studies on the production of YF vaccine in CEF cells which y ielded v ims attenuated for nonhuman primates in three consecutive production batches Its passage history is depicted in Figure 1 Vero cells were used as controls (Table ID) since these cells are known to give multiple cv cles of replication complete cytopathology and to be defective in interferon production TvuLL I RL"IIC KΛOI I~D VI I six cox] π LXTCEF Λ.XD VEROCΓLI CI ITI RIS SEED IRI S pfii/cell DILITIOX Posπxoci L \πox ixci B VΠOX IIVIL Da\ 2 Loo Aπtli ") HOI RS DΛ DA'.S "s DΛVS DA. S I) .. S Λ VIRI s YIELD FROVI CEF (Log pfu/ml) - 10 2 6 5 11 52 7 4 ^2 - 1 Ύ> - 1 " 6 0093 -20 ■ - 1 76 396 467 l 6 < 176 -.1 "6 0023 - ι 0 <-.1 76 O 446 (236) < I " 6 .1 " TD 0014 - 0 < 176 206 400 (261) < I Ύ> < 1 "6 0 oo - 5() < 176 1 " 6 296 (246) < 176 - 176 < 0 n = s 5 LlXE K r = - 0985 -0968 REORESSIOX A.XAL. SIS P = •=.001 < 0 1 k = - 0860 - 0 29 B IXTERΓEROX YIELD FROVI CEF (Log,, Units/ml) - 10 <1 30 1. )0 3 17 315 264 288 -20 < 1 30 < 1 30 2 83 257 211 218 -10 < 1 30 <1 30 2 18 178 I 70 148 -40 < 1 30 <1 30 <]a 30 148 148 148 -50 < 1 30 < 1 3 ; <la 30 (148) 130 <130 n = 4 LlXE KR r = - 0987 REORESSIOX A.XAL. SIS P = <002 k = - 0580 C RESIST XCLOI CEF TOSIXDBIS VIRI S(% PI AQI EREDI CTIOX) - 10 0 100 100 100 100 100 -20 0 100 100 100 100 100 - 30 0 30 * 100 100 100 100 -40 0 0 100 100 100 100 - so 0 0 13- 100 100 100 9 (Coxi. TUJLL I RLPLIC vπox or I7D \ iRi six coxrn EXT CEF VXD VERO ci i LCI LTΓRES) D \ iRi s YIELD ΓROVI VERO (Lou,,, Units/ml) SLI D VIRI S pfti/cell DILI TIOX PosTixoc'i L vπox IXCVBAΠOX TIME Peak LOCn,, Aπth. S HOI ' RS 1 D W 2 DA'iS 1 D .. s ^ l)\\S " DA. S - 10 2.51 177 580 7 28 617 < 1 Ύ> 1905 -20 < 1.76 101 474 719 640 <- 176 1549 - 0 I 76 (176) 411 666 659 <176 457 -40 ^ 1.76 (176) 310 501 730 < 176 1995 - 50 1.76 < 176 2.06 426 764 4 -7 l 4.365 11 = 5 5 5 LINE VR r = - 0997 - 0951 - 0974 RΓORI SIOX λ An is P = <0001 <( ) 1 < 005 k = -0912 - 0.822 - 0384 OBSERV AIIOXS (1) " PLΛQΓESIZL REDI CED (2 ) CELL CONCENTRATIONS: CEF → Initial 2 \ lO'Vml. Final I \ 10 ml in controls (3) MOI (vu Li IPLICITV OF INFECTION) VERO → Initial 1 \ lO'Vnil. Final 22 \ lO'Vml m controls CEF -» t ) 025p.nι/cellat 10 ' "' 10 As shown in Table IA and Figure 2 A CEF gave oeak 17D vims yields after 2 davs incubation and log.o yields were linearlv related to the logarithm of the vims input (r = 0 968 p ^ 0 01 ) Each tenfold decrease in vims input resulted in a 0 53 log decrease in vims yield No cvtopathic effects were observed throughout the 7 davs incubation period As expected. Vero cells gave similar yields at all virus inputs with the time to maximum titre being inversely related to the logio concentration of the vims inoculum (Table I D) On day 3 for example, yield is directly related to vims input (r = ■ + ■ 0 95 1. p <- 0 1 ) while by dav 5 this relationship is inverted (r = - 0 974, p < 0 05) Vims vield from Vero cells were about 200 times greater than those from CEF even at the lowest vims input A near total cytopathic effect was observed in all infected Vero cell cultures Vims yields in both cell types were not significantly reduced even at the highest vims input In multiple vims assavs in Vero cells, using high vims concentrations, cvtopathic effect was alvvavs observed thus no cell "sparing" occurred Reduced vield and cell ' sparin ' at high input represent the basic indicators of defective interfering particles (DI s) These results therefore constitute definitive proof that DI's play no significant role in the replication of the 17D vims However, as mentioned above, the interferon system is one of the main mechanisms which limit replication of the 17D YF vims since it is both a good inducer of IF and is sensitive to its action In the same experiment as discussed above, interferon (Table IB, Figure 2B) was induced at some level in all infected cultures of CEF with yields directly related to vims input (r = 0 987, p < 0 02) Challenging 17D YF infected cultures of CEF with Sindbis (a known IF sensitive vims) -.. various times post infection (Table IC, Figures 2C and 3) shows that all cultures were totally resistant to challenge by 3 days and to be resistant on day 2 at all except the lowest vims input tested It was concluded therefore that the induction of interferon and sensitivity to its action are the principal factors influencing the yieid of 17D vims in CEF All of the YF 17D substrains tested (DD, 5 2/VL and 5 2/DD) were shown to behave in the same manner as 17D-213 vims (discussed above) with respect to interferon induction and sensitivity These results demonstrate the necessity of infecting the cells with the vims under specific process conditions to evade the interferon svste Consistently, the use of interferon inhibitory substances would be a possible solution to increase the vims yield However, said substances are onlv poorly interferon inhibitory or can be toxic to the cells and are not acceptable as contaminants of vaccines In this regard, recent studies have also shown that the actinomycin D a known irreversible inhibitor of DNA dependent RNA synthesis, blocks the interferon response permiting multiple cycles of replication and increased YF vims yields Figure 4 shows the influence of the pretreatment of the cells with actinomvcin D and then infected with 17D YF vims This procedure gave a substantial increase in vims yield relative to control cultures This result, attributable to the inhibition of interferon production confirms that the interferon svstem is responsible for low yields But actinomycin D is relatively toxic to the cells and not acceptable as a contaminant in vaccines Thus the last aspect investigated to overcome the interferon svstem induction was the cellular density at the time of viral infection 11 The results of a typical experiment to test the effect of cell seeding density on the yield of 17DD YF vims from CEF are presented in Table II TABLE II: Ixrn LXC Γ ΈLL .SLEDIX(. DEXSI Γ . OX I HE YIELD or 17D YF V IRI S I ROVI CEF Cells/cnr Cells/ml Logm pfu/ml Yield \ 10- \ ur pfu cell Log,,, Aπl 1 0 25 (7 1 1 ) 2 71 5 13 1 0 75 7 28 2 40 25 1 1 25 6 78 1 68 47 9 7 I 75 6 30 1 06 1 1 5 9 2 25 6 15 0 80 6 1 20 5 00 5 48 - 0 22 0 6 LlXE VR REGRESS IOX n = 5 (\ alues in p larentliesi s excluded) X ALV IS r = 0 993 (p < 1 ) (log,,, cells/cnr v ersus log, ,, pfu ml) k = 2 197 (logu, \ ιeld increase for a 1 log reduction in cells) These results unequivocally demonstrate that the logio vims yield is inversely and linearlv related to the logio concentration (r = 0 994, p < 0 001) of cells seeded in the ranse of 3 x 10 to 2 x 10 ' cells/cm" In this range, a 2.2 logio increase in vims yield/ml is obtained for each logio decrease in the cell concentration At 3 x 10 4 cells/cm " , the density at which the maximal yield per millilitre was obtained, the yield per cell was 251 pfu/cell or 418 fold more than that obtained at 2 x 10 5 cells/cnr These results definitivelv prove that the infectious vims yield/ml and yield/cell is inversely related to the cell seeding density Thus, the interferon system can be evaded and efficient production established At high cell seeding densities no cytopathology was observed while at low densities, total cell death was observed about one day after peak vims yields At intermediate densities, partial cytopathology was observed According to the invention, one of the major goals in the vaccine vims production was to carry out the cell seeding with the vims at low densities, 1 e , at cell seeding densities lower than 2 x 10 " ' cells/cm 2 , preferentially at densities in the range of 1 x 10 4 - 2 x 10" cells/cm 2 and more preferentially 1 x 10 4 - 1 x 10 s cells/cm 2 Another relevant aspect in vaccine vims production is related to materials used in the culture medium since foreign proteins are not acceptable as components of human vaccines For example, fetal bovine semm proteins are not acceptable in parenteral products in view of their immunogenicity On the other hand, tests have shown that low vims yields from cell cutures, e g CEF. are obtained in the absence of fetal bovine semm (FBS) In experimental studies, yields of 17D YF vims were reduced in about 100 fold in the absence of semm Table III shows the replication of YF ( 17DD substrain) vims and induced resistance to Sindbis vims challenge in the presence and absence of semm 12 T .BLL III: REPLIC VΠOX OΓ YT I7D V IRI S AXD IXDI C LD RESISTANCE TO SIXDBIS V IRI s n vLLExor ix i nr PRLSLXC E AND ABSLXC E OΓ ERl VI Seed Dilution % Resistance to Sindbis at 48 hours Log,, WiUi FBS Without reS - 1 100 100 - 2 100 100 - 1 90 90 - 4 0 0 - 5 0 0 Controls 0 0 The results clearly demonstrate that the vims replicates well in the absence of semm and that no significant change occurs in interferon induction Indeed, the low YF vims yields from CEF in the absence of FBS can be attributed to the vims stabilising effect of the albumen fraction of FBS Therefore, according to the invention, medium supplements acceptable as components in parenteral products are used in cell cultures to stabilize the vims produced in order to obtain high vims yields, e g human semm albumen (HSA) Other substances acceptable as components in parenteral products, such as peptides, amino acids, proteins, can be used According to the invention, the cell culture to be infected by the vims may be any cell insofar as vims can replicate and which is acceptable as a substrate for vaccine production, in particular any cell type which produces interferon in which flavivimses or recombinants might grow and the same procedure of reducing cell density may be applied Specific examples include avian embryo cells and mammalian cells such as chicken embryo fibroblasts (CEF), chicken embryo cells (CE), human diploid fibroblasts (eg ΛTRC-5), monkey kidney cells, fetal Rhesus lung (FRhL) cells etc The invention is particularly suitable for the production of Flavivirus and the production of recombinant Flavivirus According to the invention, recombinant YF vims as defined in the co-pending Patent Application BR PI 9701774 may be produced, the biomass consisting of avian embryo fibroblast certified cells, in particular SPF (Specific Pathogen Free) chicken embryo fibroblast cells The co-pending Patent Application BR PI 9701774 is herein mentioned by reference The process for the production of YF 17D vaccine described here was established using several substrains of 17D vims It is, therefore, a procedure for the propagation of 17D vimses in general, be the 17D vims derived from further passaging of any existing 17D substrains or recombinant vimses derived from cloned complementary cDNA through infectious clone technology Other recombinant YF 17D vimses may include 13 1 ) chimeπc vimses for use in a vaccine preparation after propagation using the methodology of the present invention having a genome compi ising nucleic acid sequences encoding at least one structural protein from one flavivirus (represented by the clear areas, see Figure 5) and nucleic acid sequences encoding the remainder of the genome of YF 17D vims to make it functional (represented bv the black areas see Figure 5) The source of YF 17D sequences mav be plasmiαs pYF5 " 3 JV/Gl/2 and pYFM5 2/T3/27 or a other plasmids containing YF 17D vims genomic sequences The schematics of figure 5 shows on the top part the prototype stmcture of the flavivirus genome From the 5' terminus the order of the encoded proteins is the following C-PΓM/VTE, NS l NS2A- NS2B NS3, NS4A, NS4B NS5 The first 3 proteins constitute the stmctural proteins that is form the vims together with the packaged RNA molecule and were named capsid (C, 12- 14kDa) membrane (M. and its precursor prM 18-22 kDa) and envelope (E 52-54 I Da) all being encoded in the first quarter of the genome The remainder of the genome codes for the nonstmctural proteins (NS) numoered in the order of synthesis from 1 through 5 Three large nonstmctural proteins have highly conserved sequences among flaviruses NS l (38-41 kDa), NS3 (68-70 kDa) and NS5 ( fθO-103 kDa) No role has vet been assigned to NS l but NS3 has been shown to be bifunctional with a protease activity needed for the processing of the polyprotein at sites the cellular proteases will not act and a nucleotide tπphosphatase/hehcase activity being therefore also associated with viral RNA replication NS5, the largest and most conserved protein contains several sequence motifs believed to be common to viral RNA polymerases The 4 small proteins NS2A, NS2B. NS4A and NS4B are poorly conserved in their amino acid sequences but not in their pattern of multiple fr rophobic stretches NS2A has been shown to be required for proper processing of NS 1 whereas NS2B has been shown to associate with the protease acivitv of NS3 to process itself from NS3 and produce NS4B Since viral RNA synthesis takes place in the cytosol in association with RER (Rough Endoplasmic Reticulum) membranes it has been postulated that these hydrophobic proteins would be embedded in membranes and through protein-protein interactions participate in viral replication complexes together with NS3 and NS5 The short 5' (1 18 nucleotides) and 3' (51 1 nucleotides) untranslated regions contain nucleotide sequence elements some of which are conserved among the flavivimses and believed to be involved in plus and minus strand RNA replication and plus strand RNA packaging Chimeπc flavivimses mav include the capsid C through the envelope E protein, prM-E or E alone of one flavivirus and the remainder derived from a second flavivirus as indicated in the lower two parts of figure 5 Fusion between the C and prM proteins of any two flavivimses, including YF can be made at the carboxi terminus of C (its last 20 amino acids), at the cleavage site of the viral protease or at the signalase cleavage site Adjacent to the first nucleotide of the viral genome as a cloned cDNA bacterial plasmid, is a bacterial phage polvmerase promoter sequence (SP6 T7 or T3) which allows the efficient in vitro synthesis of infectious capped RNA transcripts These, in their turn, originate vims after RNA transfection of cultured cells 2) YF17D vimses expressing defined epitopes protein domains or entire proteins of other pathogens related to specific aspects of humoral or cellular immune response which can be used as a vaccine against said disease inserted within the stmctural or nonstmctural protein genes or the noncoding regions of YF 17D vims genome 14 3) YF17D v imses expressing from a sub-genomic RNA defined epitopes. protein domains or entire proteins of other pathogens related to specific aspects of humoral or cellular immune response which can be used as a vaccine against said disease In all cases above ( 1-3) the recombinant vims still contains most if not all of the YF 17D genome and therefore all major steps towards viral replication in the host cell will be the same as the original 17D vims This includes cytoplasmic replication, the participation of YF 17D viral proteins in viral RNA synthesis (plus and minus strand), polvprotein processing, capsid formation with RNA packaging, vims assemblv and budding Since all major aspects which lead to a productive infection are kept regardless of the extent of genetic modification in the cases specified above, the methodology described here will apply Therefore, according to one of the embodiments of the present invention. YF vaccine vims is produced under Good Manufacturing Practices (GMP) by infecting cells certified for human vaccine production and recovering the vims In a preferred embodiment of the present invention, to accomplish the vims propagation in cells certified for the production of human vaccines primary cultures of chicken embryo fibroblasts (CEF) are used in all production steps Cells are available and prepared according to WHO (World Health Organization) Guidelines as described bv several S O Ps (Standard Operational Procedures) Particularly in the case of YF vims, the production of YF 17D vaccine in CEF cultures, although at low yields, gave 3 lots of experimental vaccine which passed all tests including neurovirulence for monkeys The vims is prepared in primary cultures of chicken embryo fibroblasts (CEF) using eggs derived from SPF (Specific Pathogen Free) flocks The cultures of chick embryo fibroblasts (CEF) cells can be made in different forms, e g , monolavers. in suspension, in a suitable bioreactor, adsorbed to microcarπers The preparation of CEF cells is known by those skilled in the art Cell cultures are set up in a suitable medium and are later infected Vimses are recovered after incubation by centrifugation or filtration to remove cellular debris To the supernatant containing the vims a stabilizer was added which is, for those skilled in the art, known to enhance the stability of viral infectivity during freezing thawing and subsequent manipulations Vimses are stored at - 45°C or below The following examples are illustrative of the invention and represent preferred embodiments Those skilled in the art mav know, or be able to find using no more than routine experimentation, to employ other appropriate materials and techniques such as the above mentioned cells and vims production methods EXAI PLE 1 The purpose of this example is to obtain Flavivirus, in particular 17D Yellow Fever Vims in cultures of chick embryo fibroblasts (CEF) cells in monolayers as follows ( 1) SPF chick embryo tissue is converted to a cell suspension by enzymatic treatment (Day 0) This preparation is known bv those skilled in the art, (2) the cells are recovered and suspended in a suitable medium followed by seeding into monolaver culture vessels (flasks, roller bottles, multisurface propagator/ reactor etc ) at 0 1 to 1 2 ml/cm " to give 10 4 to 10' cells/cm 2 , (3) the culture is incubated for 12 to 72 hours at 30 to 40 °C, (4) the medium is removed from the monolavers and vims is added in a small volume of a suitable medium at the rate of 0 2 - 0 0001 infectious units per cell (CCID-,o, LD<o, p u). 15 (5) the vims is adsorbed for 0 5 to 4 hours at 20 to 40°C (Day 1 ), (6) a suitable maintenance medium is added at 0 1 to 1 0 ml/cm 2 with or without removal of the seed preparation and re-incubation at 30 - 40°C for 15 to 30 hours. (7) the maintenance medium is removed, and the monolayers washed once or more times and replaced with semm free maintenance medium. (8) the monolayers are re-incubated at 30 - 40°C (Day 2), after an appropriate incubation time ( e 36 to 72 hours post inoculation at 37° C), the maintenance medium containing vims is harvested (Day 3), and (9) the vims is stored at -45 to -1 6°C Multiple harvests of vims containing medium may be carried out by total or partial remov ing of the medium, at any desired interval EXAMPLE 2 The purpose ofthis example is to demonstrate the vims stabilizing effect of albumen A process as for example 1 in which human semm albumin is incorporated into the maintenance medium at 0 01 to 10 μg/ml at steps 6. 7 and 9 The Tables IV and V show the results TABLE IV: STABILITY OF YELLOW FE R V IRΓS IX VIEDUΛI CONTAINING V VRIED COXC EXTR ATIOXS OF HI MAN SERl ' ALBl'MEN Albumen concentration Log ] 0 pfii ml Half Life % \\/\ Hours at 37°C Loss/lir Hours 0 25 1 08 2 37 l 50 0 500 TNC* TNC* 2.51 2 3 1 0 IS 1 7 0 250 TNC* TNC* 2 51 2 40 0 10 3 o 0 125 TNC* TNC* 2.55 2 3 0 19 1 6 0 063 TNC* TNC* 2.48 2 33 0 13 2 3 0 03 1 TNC* TNC* 2 50 2 00 0 2^ 1 1 1 0 000 TNC* 1 00 <0 40 <0 40 < 1 80 l 40 * Too Numbered to Count These results are clearly approximations but there is a strong indication that 0 03 125% vv/v HSA is insufficient to protect vims infectivity The mean rate of loss in the presence of 0 0625 to 0 2500% w/v albumen is 0 15 logio/hour equivalent to a half life of 2 hours 16 T.ABLE V INTLΓENCE or Ht vi VN SERI VI ALBΓMEN (HSA) VND H ARV ST TIME ON THE YIELD OF YF 17D viRi's ΓROVI CEF HSA Hours Post Inoculation Log,,, Arithmetic % \\Λ pfu/ml pfu ml 0 06 29 4 81 0 6 44 6.71 85 I 48 6 82 109 6 5 6 69 81 1 68 6 04 18.2 0 20 29 5 00 1 7 44 6.70 83 2 48 6 95 147 9 53 6 85 1 17 5 68 6.23 28.2 As shown in Table V, peak titres were observed at 48 hours in the presence of 0.06 and 0.2% w/v Yield per cell is highly satisfactory with values in the region of 100 pfu/cell. Clearly therefore, HSA, which is a wholly acceptable vaccine component, gives excellent vims yields. These values should be objectively high since the samples are diluted Vi (0 3 logio) in stabilizer and assayed in a system which is 0.2 to 0.3 logio less sensitive than that used to control vims which is the final product produced by the current process, i e by using the whole chicken embryo On this basis, correction of the titres shown in Tables IV and V gives values in of 7 0 about logio pfu/ml and are equal to those obtained in the production of the whole chick embryo vaccine Example 3 The purpose of this example is to illustrate the production of Flavivims. in particular 17D Yellow Fever Vims, produced under Good Manufacturing Practices (GMP) by infecting cells certified for human vaccine preparation A total of 21 roller bottles with a surface area of 680 cm " each was used for each batch The WHO (World Health Organization) Guidelines require that 10% of flasks or a minimal volume of 500 ml of culture be used as control. For this purpose 7 flasks of 175 cm " surface area each with stationary cultures were used for each batch The preparation of each lot was accomplished by following the same pocedure as described in Example 1 Primary CEF cells obtained from eggs derived from SPF (Specific Pathogen Free) flocks were used in all lots Seed vims 17DD-LOT 102/84 was used to inoculate all cell culture Vims were recovered by pooling the medium present in every three roller into centrifuge tube and spinning at low speed to remove cellular debris The supernatant was aspirated into flasks containing stabilizer at 1 1 ratio and frozen slowly by rotating on an 17 ethanol dry ice bath after removal of all quality control aliquots All vimses are stored as indicated in Example 1. The production data are presented in the Table VI below. 18 TABLE VI: PRODI CTIOX AXD QI AI I I . CONTROL D ATA or YELLOW FEV ΓR VAC C INΓ PRODI C ED IN CHIC KEN EMBR \ o FIBROBL ASTS (CEF) i ΛDER GMP LOT Production Date Titer (lo»ι„ pfu/ml) YFCEF-LOT O I 02/02/98 6 79 YFCEF-LOT 02 03/02/98 6 68 YFCEF-LOT 03 04/02/98 6 66 YFCEF-LOT 04 05/02/98 6 " Each lot was tested for sterility potency and adventitious agents with satisfactory results EXA.MPLE 4 The purpose of this example is to describe the preparation of recombinant YF vims including chimeπc vimses bv using the process of the present invention The YF 17D vims of the Patent Application BR PI 9701774 is regenerated from plasmids pYF5 ' 3'IV/Gl/2 and pYFM5 2/T3/27 and will be hereinafter " refered to as YFιv5 2/DD Deposit of plasmids pYF5 ' 3 Tv7Gl/2 and pYFM5 2/T3/27 has been made at the American Type Culture Collection and they are identified bv ATCC Accession No 97771 and 97772, respective.y a) RNA transfection The transfection of CEF cells is carried out with LipofectAM.LNE ® (Life Technologies catalogue # 18324-012) It is a 3 1 (w/w) liposome formulation of the polycationic pid 2,3-dιoleyloxy-N-[2(spermιnecarboxιamιdo)ethyl]-N-N,dιmeth\ l-2 3- bιs(9-octadecenvloxy)- l -ropanamιnιum tπfluoro acetate) and the neutral dioleovlphosphatidyl ethanolamine (DOPE) in membrane-filtered water) at a concentration of 20 μg ml in RNase-free PBS PBS - phosphate buffer saline- is prepared and sterilized by autoclaving at 121°C for 20 minutes The Lipofect-AMINE ® is pipeted into a polystyrene 5 ml tube containing PBS Primary CEF cells are seeded and used 24 hours post seeding The transcription mix is added to the cell culture monolaver dropwise Cells are incubated for 20 minutes at room temperature Thereafter, the mix is removed by aspiration, washed with PBS and incubated for 72 hours in 199 medium The culture supernatant constitute the viral stock after addition of stabilizer The viral stock is tested for sterility, toxicity, potency and for the presence of adventitious agents The viral stock is the original seed lot The specific infectivity of the transcripts is deduced from experiments in which serial dilutions of the RNA are tranfected into Vero cells and these are overlaid with semi- solid medium Staining with crystal violet for the counting of plaques and knowing the amount of RN . as determined bv measuring the OD (optical density) at 260 nm will allow the determination of specific lnfectivitv of the transcripts (PFU/μg total RNA) 19 This determination is relevant to establishing the multiplicity of infection events that lead to the original stock It ensures an acceptable number of events equivalent to infection with live vims in order to reduce the probability of accumulation of mutations in the viral genome given the high number of replication cycles due to low RNA input b) Preparation of seed lots All lots were prepared in primary cultures of CEF cells using eggs derived from SPF (Specific Pathogen Free) flocks Vimses are recovered by pooling the supernatant present in each flask into centrifuge bottles and spinning at low speed to remove cellular debris The supernatant is aspirated into flasks containing stabilizer at 1 1 ratio and frozen slov lv by rotating on an ethanol dry ice bath after removal of all quality control aliquots All vimses are stored as indicated above b 1 ) Preparation of the original seed lot The original seed lot consists of the material derived from 3 separate transcπption/transfection experiments carried out on different days with different batches of primary CEF cultures Primary chicken embryo fibroblasts were seeded A total of 3 disposable T-flasks of 175 cm " , containing /// vitro transcribed RNA were transfected into CEF cells using LipofectAmine ® Each T-flask provided a total of 80 ml of culture supernatant In three separate transfections performed at different days and therefore with different lots of CEF cells titers for the original r.scd lots were Tl. 10 4 66 (4,66 logio pfu/ml), T2, 10 4 87 (4.87 logio pfu/ml), T3, 10 5 46 (5,46 logio pfu/ml) Each lot provided a total volume of 480 ml of original vims. Eighty ml were used for quality control remaining 400 ml for the preparation of primary seed lot(s) b 2) Preparation of primary seed lot Two primary seed lots were prepared and named LP l and LP2 LP l derives from original seed lot T3 whereas LP2 derives from T2 Each was tested for sterility, potency and adventitious agents with satisfactory results The obtained volumes and titers are Seed lot Volume (ml) Titer (log m pfti/ml) LPl 1 200 6 22 LP2 1.600 6 20 pfu= plaque-forming unit b 3) Secondary seed lots Three secondary seed lots were prepared and named LSI, LS2 and LS3 LS I and LS2 derive from primary seed lot LP l whereas LS3 derives from LP2 Each was tested for sterility, potency and adventitious agents with satisfactory results The obtained volumes and titers are Seed lot Volume (ml) Titer ( log:,, pfu 'inl) LS I 5 200 6 20 LS2 5 600 6 05 LS3 5 200 6 73 20 Each of these seed lots should suffice' for 1 T^'ac6?he pr r o--υfctiιι &in rrent manufacturing methodology (embryonated eggs) or the cellular system (CEF cells) for nearly 50 years at a rate of at least 50 million doses/ vear

Claims: 21 CLAIMS'- 1 Process for the production of vims in cell cultures comprising the steps of (a) preparing a culture of cells winch are permissive to the viais and acceptable as a substrate for vaccine production (b) suspending the cells in a suitable medium followed by cell seeding at low densities (c) incubating the cell culture at 30 to 40 °C for an appropriate period of time, (d) removing the medium from the cell culture of step (c) and inoculating with seed vims, (e) incubating the cell culture of step (d) at 25 to 40° C for an appropriate peπod of time (f) removing the medium followed by washing the cells once or more times and replacing the medium (g) incubating the cell culture of step (f) at 25 to 40° C for an appropriate period of time (h) total or partial harvesting of culture supernatant containing vims with or without addition of stabilizer (I) optionallv carrving out multiple harvests of vims containing medium at any desired interval bv replacing the removed medium and re-incubating the culture for an appropriate period. 0) optionally, removing the cell debris and whole cells from the harvested vims (1) optionallv vims mac^'vation and, (m) storing the vims at -45°C or lower 2 Process according to claim 1 wherein the cells are selected from the group consisting of chicken embrvo cells and mammalian cells which are lnterferon-producing cells when submitted to viral infection such as chicken embryo fibroblasts (CEF), chicken embryo cells (CE), human diploid fibroblasts (eg MRC-5), monkey kidney cells, fetal Rhesus lune (FRhL) cells 3 Process according to claim 1 and 2 wherein the cells are onmary or any further passaged 4 Process according to claim 1 2 and 3 wherein the cell seeding is carried out at densities lower than 2x 10 s cells/cm 2 5 Process according to claim 4 wherein the cell seeding is carried out at densities in the range of lxl 0 4 - 2x 10 "" cells/cm 2 6 Process according to claim wherein the cell seeding is carried out at densities in the range of 1x 10 4 - 1 x 10 s cells/cm 2 7 Process according to claim 1 wherein the culture is incubated at steps e g and I from 12 to 144 hours 8 Process accordine to claim 7 wherein the culture is incubated from 12 to 72 hours 22 9. Process according to claim 1 wherein stabilizer is used at step h. 10. Process according to claim 9 wherein the stabilizer is a substance acceptable as component in parenteral products and selected from the group consisting of human semm albumen (HSA), peptides. amino acids or proteins and mixtures thereof. 1 1 Process according to claim 1 to 10 wherein the vims is a wild, attenuated or recombinant vims. 12. Process according to claim 1 1 wherein the vims is a Flavivims. 13. Process according to claim 12 wherein the Flavivims is Yellow Fever vims. 14. Process according to claim 13 wherein the Flavivims is an attenuated Yellow Fever vims. 15. Process according to claim 14 wherein the Yellow Fever vims is the YF17D vims strain and substrains thereof. 16. Process for the production of recombinant vims in cell cultures comprising the steps of: (a) preparing a culture of cells which are permissive to the vims and acceptable as a substrate for vaccine production; (b) cell seeding at low densities; (c) transfecting cells with nucleic acids by treatment with synthetic lipids or electroporation; (d) incubating the cell culture at 30 to 40°C for an appropriate period of time; (e) removing the medium from the cell culture of step (d) and inoculating with seed vims; (f) incubating the cell culture of step (e) at 25 to 40°C for an appropriate period of time; (g) removing the medium followed by washing the cells once or more times and replacing the medium; (h) incubating the cell culture of step (g) at 25 to 40°C for an appropriate period of time; (i) total or partial harvesting of culture supernatant containing vims with or without addition of stabilizer, (j) optionally, earring out multiple harvests of vims containing medium, at any desired interval, by replacing the removed medium and re-incubating the culture for an appropriate period of time; (1) optionally, removing cell debris and whole cells from the harvested vims: (m) optionally, vims inactivation; and (n) storing the vims at -45°C or lower. 17. Process according to claim 16 wherein the cells are selected from the group consisting of chicken embryo cells and mammalian cells each interferon-producing cells when submitted to viral infection, such as chicken embryo fibroblasts (CEF), chicken embryo cells (CE), human diploid fibroblasts (e.g.. MRC-5), monkey kidney cells, fetal Rhesus lung (FRahaL). 23 I S Process according to claims 16 and 17 wherein the cells are pnmarv or anv further passaged 19 Process accordinsi to claims 16 17 and 18 wherein the cell seeding is carried out at densities low er than 2x 10 cells/cm " 20 Process according to claim 19 wherein the cell seeding is carried out at densities in the range of lx l 0 4 - 2x 10 "' cells/cm 2 21 Process according to claim 20 wherein the cell seeding is carried out at densities in the range of 1 \ 10 4 - lxlθ' cells/cm 2 22 Process according to claim 16 wherein the culture is incubated at steps f h and j from 12 to 144 hours 23 Process according to claim 22 wherein the culture is incubated from 12 to 72 hours 24 Process according to claim 16 wherein stabilizer is used at step I 25 Process according to claim 24 wherein the stabilizer is a substance acceptable as component in parenteral products and selected from the group consisting of human semm albumen (HS A), peptides, ar^.o acids or proteins and mixtures thereof 26 Process according to claims 16 to 25 wherein the recombinant vims is a Flav iv ims 27 Process according to claim 26 wherein the recombinant Flavivims is Yellow Fever vims 28 Process according to claims 16 to 25 wherein the recombinant vims is a chimeπc vims having a genome comprising nucleic acid sequences encoding at least one stmctural protein from one flavivims and nucleic acid sequences encoding the remainder of the genome of another Flav ivims to make it functional 29 Process according to claims 28 wherein the recombinant vims is a chimeπc vims having a genome comprising nucleic acid sequences encoding at least one stmctural protein from one flavivims and nucleic acid sequences encoding the remainder of the genome of YF 17D vims to make it functional 30 Process tor the production of Flavivims vaccine in cell cultures comprising the steps of (a) preparing a culture of cells which are permissive to the vims and acceptable as a substrate for vaccine production (b) suspending the cells in a suitable medium followed bv cell seeding at low densities (c) incubating the cell culture at 30 to 40 °C for an appropriate period of time (d) remov ing the medium from the cell culture of step (c) and inoculating w ith seed vims. 24 (e) incubating the cell culture of step (d) at 25 to 40° C for an appropriate period of time (f) removing the medium followed by washing the cells once or more times and replacing the medium, (g) incubating the cell culture of step (f) at 25 to 40° C for an appropriate period of πme (h) total or partial harvesting of culture supernatant containing vims with or without addition of stabilizer. ( I) optionally, carrying out multiple harvests of vims containing medium, at any desired interval, by replacing the removed medium and re-incubating the culture for an appropriate peπod. (j) optionally, removing the cell debris and whole cells from the harvested vims. (1) optionally, vims inactivation and. (m) optionally, lyophilizing the vaccine composition of steps h, I. j or 1 to obtain a freeze dry form of the vaccine composition 31 Process according to claim 30 wherein the cells are selected from the group consisting of chicken embryo cells and mammalian cells which are interferon-producing cells when submitted to viral infection, such as chicken embryo fibroblasts (CEF), chicken embrvo cells (CE), human diploid fibroblasts (eg MRC-5), monkey kidnev cells, fetal Rhesus lung (FRliL) 32 Process according to claims 30 and 31 wherein the cells are primary or anv further passaged 33 Process according to claims 30, 3 1 and 32 wherein the cell seeding is carried out at densities lower than 2x 10 cells/cm " 34 Process according to claim 33 wherein the cell seeding is carried out at densities in the range of 1 x 10 4 - 1x10 cells/cm" 35 Process according to claim 34 wherein the cultures of steps e, g and I are incubated from 16 to 72 hours 36 Process according to claim 30 wherein stabilizer is used in step h 37 Process according to claim 36 wherein the stabilizer is a substance acceptable as component in parenteral products and selected from the group consisting of human semm albumen (HSA), peptides, amino acids or proteins and mixtures thereof 38 Process according to claims 30 to 37 wherein the vims is a wild, attenuated or recombinant vims 39 Process according to claim 38 wherein the Flavivims is Yellow Fever vims 40 Process according to claims 38 and 39 wherein the Flavivims is an attenuated Yellow Fever vims 41 Process according to claims 39 and 40 wherein the Yellow Fever vims is the YF17D vims strain and substrains thereof

Inventors: DA SILVA FREIRE MARCOS, GALLER RICARDO, MANN GEORGE FOBES, YAMAMURA ANNA MAYA YOSHIDA, DA SILVA FREIRE, MARCOS, GALLER, RICARDO, MANN, GEORGE, FOBES, YAMAMURA, ANNA, MAYA, YOSHIDA
Applicants: DA SILVA FREIRE MARCOS, FUNDACAO OSWALDO CRUZ, GALLER RICARDO, MANN GEORGE FOBES, YAMAMURA ANNA MAYA YOSHIDA, DA SILVA FREIRE, MARCOS, FUNDACAO OSWALDO CRUZ - FIOCRUZ, GALLER, RICARDO, MANN, GEORGE, FOBES, YAMAMURA, ANNA, MAYA, YOSHIDA
Application year: 1999
Main classification: C12N5
IPC codes: A61K39, A61P31, C12N5, C12N7